1. Khavjou, Olga, D. Phelps, and A. Leib. “Projections of cardiovascular disease prevalence and costs: 2015–2035.” Dallas: American Heart Association (2016).

THERMOCOOL^® Catheters are approved for drug refractory recurrent symptomatic paroxysmal atrial fibrillation, when used with CARTO^® 3 Systems (excluding NAVISTAR^® RMT THERMOCOOL^®Catheter).

Caution: US law restricts this device to sale by or on the order of a physician. Important information: Prior to use, refer to the instructions for use supplied with this device for indications, contraindications, side effects, warnings and precautions.


This site is published by Biosense Webster, Inc. which is solely responsible for its contents.
This site is intended for residents of the United States.
Third party trademarks used herein are trademarks of their respective owners.
^©Biosense Webster, Inc. 2020 All rights reserved 126850-191103